Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 8 | 2023 | 744 | 1.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2023 | 930 | 1.270 |
Why?
|
| Endometrial Neoplasms | 5 | 2023 | 193 | 0.930 |
Why?
|
| Bevacizumab | 5 | 2020 | 281 | 0.920 |
Why?
|
| Genital Neoplasms, Female | 4 | 2020 | 107 | 0.890 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 250 | 0.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 2436 | 0.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 407 | 0.650 |
Why?
|
| Sirolimus | 3 | 2012 | 169 | 0.580 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 2357 | 0.480 |
Why?
|
| Radiosurgery | 3 | 2021 | 272 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 1313 | 0.430 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 74 | 0.410 |
Why?
|
| Postmenopause | 2 | 2007 | 98 | 0.370 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 2887 | 0.360 |
Why?
|
| Endometrium | 2 | 2023 | 48 | 0.360 |
Why?
|
| Carcinoma | 2 | 2011 | 436 | 0.350 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 24 | 0.310 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 557 | 0.300 |
Why?
|
| Breast Diseases | 1 | 2007 | 97 | 0.300 |
Why?
|
| Cervix Uteri | 1 | 2007 | 65 | 0.300 |
Why?
|
| Doxorubicin | 3 | 2012 | 295 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 1376 | 0.280 |
Why?
|
| Aged | 13 | 2023 | 18402 | 0.280 |
Why?
|
| Female | 22 | 2023 | 44507 | 0.270 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 938 | 0.250 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2023 | 62 | 0.240 |
Why?
|
| Maytansine | 1 | 2023 | 9 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2022 | 262 | 0.230 |
Why?
|
| Neoplasms | 4 | 2021 | 2897 | 0.220 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2023 | 43 | 0.220 |
Why?
|
| Quinazolines | 1 | 2023 | 220 | 0.210 |
Why?
|
| Piperazines | 1 | 2023 | 272 | 0.210 |
Why?
|
| Indoles | 1 | 2023 | 318 | 0.210 |
Why?
|
| Middle Aged | 11 | 2021 | 25017 | 0.210 |
Why?
|
| Humans | 22 | 2023 | 86601 | 0.180 |
Why?
|
| Adult | 9 | 2021 | 25640 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6501 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 311 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 301 | 0.160 |
Why?
|
| Survival Rate | 3 | 2020 | 1860 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2011 | 56 | 0.120 |
Why?
|
| ras Proteins | 2 | 2011 | 128 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 154 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2011 | 137 | 0.120 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1056 | 0.110 |
Why?
|
| Phthalazines | 2 | 2023 | 39 | 0.110 |
Why?
|
| Age Factors | 2 | 2007 | 1849 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7988 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 114 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 270 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 645 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 128 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 199 | 0.090 |
Why?
|
| Mutation | 2 | 2011 | 3967 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 916 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 35 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1204 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 182 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 322 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 70 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 178 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 176 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.080 |
Why?
|
| Prognosis | 4 | 2020 | 3674 | 0.080 |
Why?
|
| DNA Probes, HPV | 1 | 2007 | 3 | 0.080 |
Why?
|
| Endometrial Hyperplasia | 1 | 2007 | 8 | 0.080 |
Why?
|
| Uterine Hemorrhage | 1 | 2007 | 19 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 108 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1961 | 0.080 |
Why?
|
| Premenopause | 1 | 2007 | 54 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 185 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 68 | 0.070 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 135 | 0.070 |
Why?
|
| Gynecology | 1 | 2008 | 124 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1685 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2008 | 359 | 0.060 |
Why?
|
| Folate Receptor 1 | 1 | 2023 | 2 | 0.060 |
Why?
|
| Platinum Compounds | 1 | 2023 | 31 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1169 | 0.060 |
Why?
|
| Dasatinib | 1 | 2023 | 37 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 72 | 0.060 |
Why?
|
| Fallopian Tubes | 1 | 2023 | 41 | 0.060 |
Why?
|
| Peritoneum | 1 | 2023 | 57 | 0.060 |
Why?
|
| Risk Factors | 2 | 2019 | 5416 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2023 | 106 | 0.060 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.060 |
Why?
|
| Ribose | 1 | 2022 | 17 | 0.060 |
Why?
|
| Adolescent | 2 | 2012 | 8979 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 52 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 8 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 10 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 40 | 0.050 |
Why?
|
| Epigenomics | 1 | 2022 | 100 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 224 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2008 | 754 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 1937 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 433 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 252 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1034 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 592 | 0.050 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 72 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5974 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 291 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2019 | 146 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 468 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 213 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 468 | 0.040 |
Why?
|
| Male | 4 | 2021 | 40956 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1384 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1161 | 0.030 |
Why?
|
| Metaplasia | 1 | 2011 | 37 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 167 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2270 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 183 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 45 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 223 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 48 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 384 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 129 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 299 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 927 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 894 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 372 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 8475 | 0.010 |
Why?
|